Literature DB >> 31773787

Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas.

Leandro Kasuki1,2,3, Ximene Antunes1, Maria Caroline Alves Coelho1, Elisa Baranski Lamback1, Sarah Galvão1, Aline Helen Silva Camacho4, Leila Chimelli4, Nina Ventura5, Mônica R Gadelha1,2,4.   

Abstract

INTRODUCTION: A single study suggested that silent corticotropinomas (SCAs) have a different imaging phenotype, with microcystic aspect on T2-weighted sequence of magnetic resonance imaging (T2-MRI). This study only analysed manifest and silent corticotropinomas and nonfunctioning gonadotroph adenomas. Therefore, the prevalence of microcystic patterns of other tumours is not known. AIM: To analyse frequency of microcystic patterns on T2-MRI in all subtypes of pituitary adenomas and determine accuracy of this radiological finding for diagnosing SCA.
METHODS: Consecutive pituitary adenoma patients who underwent surgery between 2013 and 2016 at a single centre were included. T2-MRIs were evaluated by a radiologist and an endocrinologist blinded to histological diagnosis.
RESULTS: A total of 143 patients (52% female) with median age of 49 years (14-80) were included. Clinically, there were 90 nonfunctioning pituitary adenomas (NFPAs), 32 somatotropinomas, 13 corticotropinomas, five prolactinomas and three TSH-secreting adenomas. Of the patients with NFPA, 12 (13%) were SCAs, 73 (79%) were gonadotropinomas and five (6%) were positive for prolactin (three) or TSH (two). A microcystic pattern was observed in 16 tumours (11%): one somatotropinoma, one corticotropinoma, seven SCAs and seven gonadotropinomas, and in no prolactinomas or TSH-secreting adenomas. It was more common in SCAs than in other tumours (58.3% vs 6.9%, respectively, P < .001) and had a sensitivity of 58%, a specificity of 93% and an accuracy of 90% to define an SCA.
CONCLUSION: Microcystic aspect on T2-MRI is able to define SCA with a good accuracy and can be a useful tool, considering the more aggressive behaviour of these tumours.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  aggressiveness; microcystic pattern; nonfunctioning pituitary adenomas; silent corticotropinoma

Mesh:

Year:  2019        PMID: 31773787     DOI: 10.1111/cen.14133

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.

Authors:  Guangyao Zheng; Lin Lu; Huijuan Zhu; Hui You; Ming Feng; Xiaohai Liu; Congxin Dai; Yong Yao; Renzhi Wang; Huabing Zhang; Xu Sun; Zhaolin Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-23       Impact factor: 5.555

2.  Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.

Authors:  Keyi Zhang; Xuefei Shou; Hong Chen; Nidan Qiao; Wenqiang He; Zhengyuan Chen; Ming Shen; Shiqi Li; Yao Zhao; Zhaoyun Zhang; Yiming Li; Hongying Ye; Yongfei Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-18       Impact factor: 5.555

Review 3.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

4.  Application of "mosiac sign" on T2-WI in predicting the consistency of pituitary neuroendocrine tumors.

Authors:  Ding Nie; Peng Zhao; Chuzhong Li; Chunhui Liu; Haibo Zhu; Songbai Gui; Yazhuo Zhang; Lei Cao
Journal:  Front Surg       Date:  2022-07-26

5.  Difference in miRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of miRNA in the Regulation of Corticosteroid Receptors.

Authors:  Beata J Mossakowska; Paulina Kober; Natalia Rusetska; Joanna Boresowicz; Maria Maksymowicz; Monika Pękul; Grzegorz Zieliński; Andrzej Styk; Jacek Kunicki; Tomasz Mandat; Mateusz Bujko
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.